Experimental mRNA cancer vaccine shows promise in extending melanoma patient lives

A significant breakthrough in cancer treatment has emerged with an experimental mRNA therapeutic vaccine showing promise for patients with high-risk melanoma. This innovative approach, a collaboration between Moderna and Merck, does not prevent cancer but significantly extends the lives of those affected by it.

“

Yeah, this can be highly significant. This is something that we've been working on for 30 or 40 years right now, and what's changed is that we have the ability to find proteins on the surface of cancer cells that can be used to try to train the immune system to identify cancer and prevent cancer recurrence.

Dr. Scott Gottlieb, former FDA Commissioner, explained that the treatment is a form of cancer immunotherapy that has been in development for 30 to 40 years. The key advancement lies in the ability to identify specific proteins on the surface of cancer cells. mRNA is used to train the body's immune system, specifically T cells, to recognize and attack cancer cells should they recur in other parts of the body.

“

And so, this isn't a vaccine in a traditional sense. This is a form of cancer immunotherapy. We are delivering mRNA to try to train the body on proteins that are found on the surface of cancer cells, so that you can teach the T cells in the body to spot the cancer should it recur.

While full trial results are pending, initial findings indicate that the vaccine is effective in preventing cancer recurrence. By training the body on these specific antigens, T cells become equipped to spot and combat cancer if it reappears. This represents a crucial step forward in harnessing the immune system to fight the disease.

“

And what the trial demonstrated, and we don't have the full results, we have to wait for the top line results to come out, but what the trial demonstrated was that it prevents cancer recurrence, so that basically, when the body is trained on these specific antigens, the T cells can be- be able to spot the cancer if it should recur in other parts of the body.

Addressing the White House's assertion that the breakthrough vindicates reduced federal funding for mRNA research, Gottlieb clarified that such statements likely pertain to mRNA vaccines for infectious diseases. He emphasized that this cancer therapeutic is distinct and represents a different application of mRNA technology. The development highlights the ongoing progress in utilizing mRNA technology for therapeutic purposes beyond infectious disease prevention.

“

Yeah, look, I think that the statements from HHS pertain, in particular, to mRNA vaccines used for infectious diseases. This is different. Like I said, this is not a va